Do Kim
Stock Analyst at Piper Sandler
(2.02)
# 2,741
Out of 4,814 analysts
98
Total ratings
44%
Success rate
0.54%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $28.32 | +122.46% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $14.92 | +208.31% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $489.10 | -39.48% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $104.53 | +7.15% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $25.21 | +245.10% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $2.12 | +984.91% | 2 | Jan 19, 2023 | |
| AFMD Affimed | Maintains: Overweight | $70 → $60 | $0.73 | +8,119.18% | 6 | Dec 12, 2022 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $16.88 | +18.48% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $7.96 | +440.20% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $36.06 | -11.26% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $22 | $2.42 | +810.97% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $30.73 | -38.17% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $2.02 | +692.08% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $234.75 | -21.19% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $8.55 | +10,426.32% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $58.66 | -40.33% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $1.12 | +1,685.71% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $28.32
Upside: +122.46%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $14.92
Upside: +208.31%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $489.10
Upside: -39.48%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $104.53
Upside: +7.15%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $25.21
Upside: +245.10%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $2.12
Upside: +984.91%
Affimed
Dec 12, 2022
Maintains: Overweight
Price Target: $70 → $60
Current: $0.73
Upside: +8,119.18%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $16.88
Upside: +18.48%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $7.96
Upside: +440.20%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $36.06
Upside: -11.26%
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $2.42
Upside: +810.97%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $30.73
Upside: -38.17%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $2.02
Upside: +692.08%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $234.75
Upside: -21.19%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $8.55
Upside: +10,426.32%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $58.66
Upside: -40.33%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $1.12
Upside: +1,685.71%